ImmunityBio, Inc. Revenue 2013–2025
ImmunityBio, Inc. annual/quarterly revenue history and growth rate from 2013 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- ImmunityBio, Inc. revenue for the quarter ending March 31, 2026 was 44.2 M, a 167.64% increase year-over-year.
- ImmunityBio, Inc. revenue for the twelve months ending March 31, 2026 was 119.2 M, a 1538.61% increase year-over-year.
- ImmunityBio, Inc. annual revenue for 2025 was 113.3 M, a 668.31% increase from 2024.
- ImmunityBio, Inc. annual revenue for 2024 was 14.7 M, a 2270.58% increase from 2023.
- ImmunityBio, Inc. annual revenue for 2023 was 622000, a 159.17% increase from 2022.
- ImmunityBio, Inc. annual revenue for 2022 was 240000.
ImmunityBio, Inc. (IBRX) — Frequently Asked Questions
ImmunityBio, Inc. (IBRX) is a publicly traded US company. It has a market capitalization of $6.42B. In fiscal 2025 it reported revenue of $113M and net income of -$351M. Explore IBRX's stock price, financial statements, earnings history, margins and key ratios below.
What is ImmunityBio, Inc.'s market cap?
ImmunityBio, Inc. (IBRX) has a market capitalization of $6.42B.
What is the IBRX stock price?
IBRX trades at $6.98 (-3.72% on the day).
How much revenue does ImmunityBio, Inc. make?
ImmunityBio, Inc. reported revenue of $113M in fiscal 2025.
Is IBRX profitable?
In fiscal 2025, ImmunityBio, Inc. reported net income of -$351M.